PDT reduces choroidal thickness

Article

Low-fluence photodynamic therapy (PDT) decreases subfoveal choroidal thickness (SFCT) in central serous chorioretinopathy (CSC), states a paper in the journal Eye.

Low-fluence photodynamic therapy (PDT) decreases subfoveal choroidal thickness (SFCT) in central serous chorioretinopathy (CSC), states a paper in the journal Eye.

Dr N.H. Kang et al., Department of Ophthalmology, Ewha Womans University, School of Medicine, Mok-dong Hospital, Seoul, Republic of Korea, conducted a retrospective study on 36 consecutive eyes of 36 patients. Of the eyes included in the investigation, there were 16 with spontaneously resolved CSC and 20 eyes with PDT-treated CSC. At each visit BCVA and SFCT were evaluated until complete absorption of the retinal fluid. There was also a control group that consisted of 32 normal subjects.

Baseline SFCT was 459.16±77.50 μm and decreased to 419.31±54.49μm after a spontaneous resolution. SFCT in the PDT group was 416.43±74.01 and 349.50±88.99 μm at baseline and after spontaneous resolution, respectively.

Patients with CSC decreased after both spontaneous resolution and low-fluence PDT. However, only the PDT group experienced a decrease comparable to that of the control subjects.

The abstract can be read here.

Related Videos
ARVO 2024: Andrew D. Pucker, OD, PhD on measuring meibomian gland morphology with increased accuracy
 Allen Ho, MD, presented a paper on the 12 month results of a mutation agnostic optogenetic programme for patients with severe vision loss from retinitis pigmentosa
Noel Brennan, MScOptom, PhD, a clinical research fellow at Johnson and Johnson
ARVO 2024: President-elect SriniVas Sadda, MD, speaks with David Hutton of Ophthalmology Times
Elias Kahan, MD, a clinical research fellow and incoming PGY1 resident at NYU
Neda Gioia, OD, sat down to discuss a poster from this year's ARVO meeting held in Seattle, Washington
Eric Donnenfeld, MD, a corneal, cataract and refractive surgeon at Ophthalmic Consultants of Connecticut, discusses his ARVO presentation with Ophthalmology Times
John D Sheppard, MD, MSc, FACs, speaks with David Hutton of Ophthalmology Times
Paul Kayne, PhD, on assessing melanocortin receptors in the ocular space
Osamah Saeedi, MD, MS, at ARVO 2024
© 2024 MJH Life Sciences

All rights reserved.